EGFR and non-small cell lung carcinoma: Indeed, in advanced NSCLC, liquid biopsy is now used as a diagnostic assay to investigate EGFR-sensitizing mutations at baseline, when tissue is not adequate, or to detect the acquired resistance EGFR T790M mutation at disease progression [7].